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Abstract The current evidence of PSA-based prostate
cancer screening shows a reduction in cause-specific
mortality, but with substantial overdiagnosis. Recently,
new developments in detection of clinically relevant
prostate cancer include multiple kallikreins as biomarkers
besides PSA, and multiparametric magnetic resonance
imaging (mpMRI) for biopsy decision. They offer oppor-
tunities for improving the outcomes in screening, particu-
larly reduction in overdiagnosis and higher specificity for
potentially lethal cancer. A population-based randomized
screening trial will be started, with 67,000 men aged
55–67 years at entry. A quarter of the men will be allocated
to the intervention arm, and invited to screening. The
control arm will receive no intervention. All men in the
screening arm will be offered a serum PSA determination.
Those with PSA of 3 ng/ml or higher will have an
additional multi-kallikrein panel and those with indications
of increased risk of clinically relevant prostate cancer will
undergo mpMRI. Men with a malignancy-suspect finding
in MRI are referred to targeted biopsies. Screening interval
is 6 years for men with baseline PSA\ 1.5 ng/ml, 4 years
with PSA 1.5–3.0 and 2 years if initial PSA[ 3. The main
outcome of the trial is prostate cancer mortality, with
analysis at 10 and 15 years. The statistical power is suffi-
cient for detecting a 28% reduction at 10 years and 22% at
15 years. The proposed study has the potential to provide
the evidence to justify screening as a public health policy if
mortality benefit can be sustained with substantially
reduced overdiagnosis.
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Introduction
Prostate cancer is one of the key medical and public health
challenges at the moment: It is the most common cancer
among men in Western countries, and the second most
common cause of cancer death in men in Finland and third
in Europe [1]. The prostate cancer epidemic is, however,
largely iatrogenic, as the increase in incidence is
attributable predominantly to increased serum prostate-
specific antigen (PSA) testing. A substantial proportion of
the cases detected at an asymptomatic stage represent
overdiagnosis, as relative survival from localized prostate
cancer at 5 years approaches—or in some studies
exceeds—100% [2–4] Hence, not all cases benefit from
active curative management. Overdiagnosis is defined as
detection of disease that would not have caused any harm
during a man’s lifetime, i.e. unnecessary detection of latent
disease of dubious clinical relevance. It involves adverse
effects of treatment (e.g. erectile dysfunction and urinary
incontinence) without therapeutic benefit to the patient.
Overdiagnosis is more extensive in prostate cancer
screening than other cancer screening programs—mod-
elling studies have estimated that it amounts to 40% of the
screen-detected case [5], or three excess cases per 100 men
invited to screening [6].
Screening frequency is an important determinant of
overdiagnosis [7]. Etzioni et al. [8] estimated that 27% of
overdiagnosis could be reduced by using longer screen-
ing intervals in men with low PSA. Overdiagnosis is
most common in the oldest age groups, which is one of
the reasons why conservative policy should be adopted
for men older than 70 years [7, 8]. Comparable results
were also found in the Finnish screening trial (FinRSPC)
[6].
Screening can potentially offer a means for reducing
prostate cancer mortality. The PSA-based European ran-
domised screening trial (ERSPC) showed a 20% reduction
in prostate cancer mortality at 13 years of follow-up [9].
The absolute screening effect has increased with follow-
up (781 men needed to invite to avert one prostate cancer
death at 13 years) and it is comparable to the well-
established cancer screening modalities (number needed
to screen for preventing a cancer death in the range
800–1000 in mammography screening for breast cancer
and fecal occult blood testing for colorectal cancer)
[10, 11].
Modelling studies have shown varying estimates of
overall quality of life impact and cost-effectiveness for
prostate cancer screening [12–14]. The frequent adverse
effects have so far tipped the balance against prostate
cancer screening, and therefore we will focus on employing
the best available means for reducing them.
What is the optimal screening test?
Even though PSA is one of the best cancer biomarkers
developed, it has turned out to be insufficient as a stand-
alone test for prostate cancer screening, due to low speci-
ficity for clinically relevant cancer. The best option for
improving performance of PSA as a screening test is to
combine it with other biochemical indicators. A panel of
four kallikreins (total PSA, free PSA, intact PSA and
human kallikrein-related peptidase-2, hK2), known as the
4Kscore has been developed to indicate the probability of
an aggressive prostate cancer [15]. In four studies, it
reduced the number of biopsies by 25–43%, while detect-
ing 89–97% of GS C 7 cases with AUC 0.78–0.84
[15–18]. Yet, it has never been applied as a screening tool
in a randomized trial.
The Prostate Health Index (PHI) is another multicom-
ponent biochemical risk indicator (with total, free and pro-
PSA) with reasonably similar performance as 4Kscore, but
its characteristics have not been equally well documented
[19, 20].
Optimizing the diagnostic process for clinically
relevant cancer
Major developments have been made with magnetic reso-
nance imaging of the prostate during the past years. An
endorectal coil has been replaced by a pelvic coil, and
imaging sequences have been substantially improved.
Targeted biopsies guided by multiparametric MRI
(mpMRI) has been shown to decrease the frequency of
biopsied men by 20–54% compared to systematic tran-
srectal ultrasound-guided biopsies, with a substantial
reduction in detection of GS\ 7 cancer (20–54%). Nev-
ertheless, MRI-guided biopsies retain a very high sensi-
tivity (90–93%) for Gleason 7? prostate cancer in
previously non-biopsied men [21–23] The positive pre-
dictive value in such biopsies among men with elevated
PSA has ranged 38–66% [22]. The recent PROMIS trial
using the latest technique and procedures with 576 men
showed a sensitivity of 93%, with a positive predictive
value of 51% and a negative predictive value of 89% [23].
Hence, MRI can reduce both the number of biopsied men
and the number of cores per man by focusing only lesions
visualized through MRI, thought to reveal neoplastic tissue
with Gleason pattern 4–5 suggestive of potentially
aggressive cancer, but not pattern\4 indicating low-risk
disease. Use of directed biopsies has the additional benefit
of decreasing biopsy complications. Further, targeting the
suspect lesion can decrease the proportion of cancers
missed—estimated around 25% for systematic 10–12 core
biopsy (mainly in the anterior, apex and midline of the
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prostate) [24]. Superior sensitivity for MRI-based targeted
biopsy than TRUS-based systematic biopsy for Gleason 7?
cancer has been shown in several studies [21]. Hence,
mpMRI complements the biomarkers in screening as the
final step in selection of high-risk men for biopsy.
The main objective of the ProScreen trial is to assess the
impact of early detection through screening on prostate
cancer mortality, when the main adverse effect, i.e. over-
diagnosis is minimized using the best potential methods for
avoiding it: a kallikrein panel, multiparametric MRI and a
flexible screening interval (Fig. 1). Each of the methods
has been shown to reduce the detection of Gleason \7
prostate cancer by at least a third, while missing only
10–15% of the more aggressive cases. Their combined
effect has not, however, been studied.
The challenge is in maintaining the mortality benefit, i.e.
decreasing detection of non-progressive disease without
missing the clinically relevant cases. Ideally, a screening
regimen specific for aggressive disease would eliminate the
need for active surveillance, as it is used for low-risk
cancers only. Reducing overdiagnosis is a key to improving
the balance of benefits and harms, but reduction in prostate
cancer mortality is required to justify screening.
The rationale of the ProScreen trial is to optimize the
outcomes by refining the screening process through three
layers of risk assessment to identify men at elevated risk of
potentially lethal cancer. The early risk stratification stage
is assessed in terms of diagnostic accuracy (specificity and
sensitivity as well as receiver operating characteristic, ROC
for clinically relevant cancer) as an interim end-point. In
addition, novel screening methods are evaluated besides
those used for decision making and subsequently analysis
of effectiveness (mortality effect). The latter analyses are
not based on randomization, but observational comparison
of alternative tests. This will increase the frequency of
referrals, as evaluation of the more experimental methods
used as ancillary tests also requires diagnostic assessment




We will identify all 67,000 men aged 55–67 years and
residing in Tampere or Helsinki, and randomize them into
two trial arms with 1:3 allocation. Men with prevalent
prostate cancer will be identified through the Finnish
Cancer Registry and excluded (expected number is 200,
based on prevalence 0.3% at entry to our previous
FinRSPC trial).
Screening procedure
A 30 ml blood sample will be drawn to an EDTA tube,
with plasma and serum separated and frozen. The extensive
network of [100 local hubs in the region is essential,
enabling easy access for all men, as well as efficient sample
processing and transportation. The blood and urine will be
analysed within 4 weeks of the sample to allow timely
screening decision-making based on the risk stratification
results. PSA determination will be performed using WHO
calibration and continuous quality assurance programs with
certified performance.
Additional analyses of biomarkers will be conducted for
men with PSA C 3 ng/ml (expected number 1520 men in
the first round) to determine who are screen-positive. A
multi-kallikrein panel will be used to identify men at
increased risk of an aggressive prostate cancer (out of those
with PSA[ 3). They will be regarded as screen-positive
and referred to diagnostic examination at the local
University Hospital urology clinic. Men with PSA density
[0.15 will also be referred to biopsy to improve sensitiv-
ity. The expected frequency of screen-positive men refer-
red to MRI is 912 men in the first round (60% of the men
with PSA C 3).
The screen-positive men will undergo a multiparametric
MRI using 3T equipment with 32-channel pelvic phased-
array coil. T2-weighted, diffusion-weighted and dynamic
contrast-enhanced imaging is employed in accordance with
the European Society for Urogenital Radiology guideline
(‘‘Appendix’’) [25]. The findings will be classified
according to the Prostate Imaging Reporting and Data
System (PIRADS-2), which is a 5-point scale to combine
the MRI findings and indicate the likelihood of a significant
cancer [26]. MP-MRI scans are evaluated by specialized
urologic radiologists with substantial experience in prostate
imaging. In centralized training, a sample of cases will be
Fig. 1 A schematic representation of the risk stratification algorithm
in the ProScreen trial (risk pyramid)
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first reviewed individually, scored, and then reviewed as a
group. Further training will be arranged during the trial. To
assess inter-observer agreement, a sample of patient scans
will re-evaluated in a blinded fashion.
Prostate biopsies are processed in pathology laboratories
in Helsinki (HUSLAB) and Tampere (Fimlab Laborato-
ries). Both are accredited testing laboratories according to
the standard SFS-EN ISO 15,189:2013. The biopsies are
evaluated by experienced uropathologists at both hospitals
using standardized procedures [27], with amount of
malignant tissue and Gleason pattern evaluated separately
for each biopsy core. Standardization and quality control of
clinical chemistry, radiology and pathology is ensured
before the launch of the trial.
The expected number of screen-detected cases in the
first round is 365. A flowchart of the trial with the expected
numbers of men is shown in Fig. 2. The expected numbers
were obtained from previous research (the Finnish results
of the ERSPC trial for participation, PSA distribution
[9, 28], Assel et al. (submitted) for 4Kscore distribution,
and MRI results [21–23]).
Buffy coat will also be obtained for DNA extraction
from all participants. Urine samples are obtained from all
men in Tampere (a quarter of the population), as well as all
screen-positive men referred to MRI for development of
new markers of risk and prognosis.
Follow-up
Information on prostate cancer cases diagnosed in the
entire study population will be obtained from the Finnish
Cancer Registry. Detailed clinical information on Gleason
score, PSA at diagnosis, treatment and other features will
be abstracted from the medical records at each hospital.
Follow-up for vital status and emigration is through Pop-
ulation Registry, and causes of death will be obtained from
Statistics Finland. We have previously evaluated the
accuracy of the official causes of death for prostate cancer
and shown an excellent agreement with a blinded expert
panel [28, 29].
The main outcome of the trial is mortality from prostate
cancer. The analysis of the main end-point is based on the
intention to screen principle, i.e. comparing groups defined
by the random allocation, regardless of compliance. Based
on the age-specific Finnish population rates, at 10 years of
follow-up (allowing for mortality from other causes esti-
mated from the current age-specific lifetables), we expect
475,000 person-years with 222 prostate cancer deaths in
the control arm. Using these figures, the minimal
detectable difference (a = 0.05 two-sided and
1 - b = 0.8) between the arms is 28% at 10 years
(RR B 0.72). At 15 years, the predicted number of prostate
cancer deaths in the control arm is 451, with sufficient
statistical power to show a 22% reduction.
For the diagnostic accuracy studies of the main
screening tests and the novel methods such as eNose and
urine kallikreins, a sample size of 10,638 is needed to
demonstrate a sensitivity of 0.9 with 5% margin of
uncertainty, assuming binary results and the prevalence of
clinically relevant prostate cancer of 1.3%. Not all men
will be biopsied for diagnostic confirmation, but the anal-
ysis will rely on incidence method, with the true disease
status being revealed with sufficient follow-up, say 5 years
[30]. For ROC estimation, the expected number of
Fig. 2 A flow chart of the ProScreen trial. N(exp) stands for expected number
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screened men with assumed 1.3% prevalence of clinically
relevant cancer would provide roughly 9% confidence
interval width for diagnostically relevant ROC values
(0.7–0.8).
The recruitment will commence in 2018 (trial year 1).
The target population will be identified and randomized at
Population Registry, with invitations for the screening arm
sent from early 2018. The first screening round will be
completed in 2019 and screening-positive men will be re-
invited after 2 years (2020–2021), and for the second time
in 2022–23 (Table 1). For the screen-negative men, the
second screening round will take place after this (4-year
interval 2022–2023, 6-year 2024–2025), overlapping with
the subsequent screening rounds for the screen-positive
men at each round.
A data monitoring committee will be established, with
the main adverse outcome defined as incidence of
advanced prostate to ensure that a large fraction of cases
are not missed in the intervention arm. The trial can be
stopped early for benefit or harm, if evidence for difference
between the arms is obtained. For assessment of harm from
the intervention, biopsy and treatment complications will
be analysed, as well as incidence of advanced cancer (as an
indicator of cancers missed by screening) and Gleason\7
cancer (as indicator of overdiagnosis) by arm are per-
formed annually for the data monitoring committee.
Monitoring of the main end-point (prostate cancer mor-
tality) is carried out by an external committee. Interim
analyses are performed at 5 and 8 years in accordance with
sequential analysis rules (total alpha spending 0.005 of the
two interim analyses according O’Brien-Fleming).
Discussion
The trial investigates whether new developments in the
diagnosis of clinically relevant prostate cancer, magnetic
resonance imaging and combination of several kallikreins
as biomarkers, can be translated into a screening program
that would achieve reduction in prostate cancer mortality,
while avoiding the major adverse effect of overdiagnosis
hampering the PSA-based efforts. The large-scale, popu-
lation-based effectiveness design ensures that the evidence
obtained will be readily applicable in real-world clinical
and public health decision-making.
The advantages of the study include a population-based
design, with the target population identified from the
comprehensive population center; a Zelen-type random-
ization further enhances the generalizability, as men in the
control arm will not need to be contacted for inclusion in
the follow-up.
The selection of the PSA cut-off requires consideration
of the relative importance of sensitivity and specificity.
PSA levels increase with age and strongly predict lethal
prostate cancer well before clinical stage of the disease
[31, 32]. An aggressive screening policy would use a lower
threshold, with lower specificity and higher sensitivity.
This would likely maximize the mortality reduction, but
also increase the cost and adverse effects. PSA threshold of
3 ng/ml was used in the ERSPC trial [9], while 4 ng/ml
was used in the PLCO [33].
Major challenges for the trial include maintaining a high
adherence. In the earlier Finnish randomized prostate
cancer screening trial, participation was 67%, and the
ProScreen trial is expected to achieve similar compliance.
Another concern is the extent of opportunistic PSA testing
in the population. In the previous trial, PSA testing rates
were high in the control arm particularly in the early 2000s
[34]. However, prostate cancer incidence rates declined by
a fifth from the peak levels in Finland (as in several other
countries) during the past decade, likely indicating
decrease in the opportunistic screening [35]. A continuing
decline in population mortality rates may also decrease the
predicted power of the trial. As for achieving a mortality
impact, a delicate balance needs to be achieved in treat-
ment, avoiding both overtreatment of non-aggressive cases
to avoid adverse effects, while providing effective man-
agement of potentially progressive disease for reducing
mortality. As prostate cancer has only a minor contribution
to overall mortality (3% of all deaths in men), no reduction
in overall mortality can be expected.
The target effect size of a reduction in prostate cancer
mortality by approximately a quarter is ambitious.
Reducing overdiagnosis and avoiding detection of cases of
low malignancy will inevitably decrease the mortality
impact to some extent. If both kallikrein panel and MRI
Table 1 Schedule of the study
Trial years 1–2 Years 3–4 Years 5–6 Years 7–8 Years 9–10
All subjects Recruitment
All participants 1st screening
Men with PSA[ 3 2nd screen 3rd screen 4th screen 5th screen
Men with PSA 1.5–3 2nd screen 3rd screen
Men with PSA\ 1.5 2nd screen
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have sensitivity of 90%, the reduction in detection of
clinically relevant cancer may be 20% (0.9 9 0.9 = 0.81,
compared with PSA alone), with a corresponding loss of
mortality benefit. Yet, using a 2-year screening interval in
men with PSA 3 ng/ml or higher will likely counterbalance
this and most aggressive cases will be detected at subse-
quent rounds, optimally still at organ-confined stage.
As a pragmatic trial, any developments in prostate
cancer diagnostics will be implemented (to both trial arms),
as they are adopted into clinical practice. For instance, MRI
protocols are being refined and biparametric imaging may
simplify the procedure and reduce the costs [36].
A randomized trial provides the most scientifically rig-
orous evidence, and our previous experience shows that it
can yield material for extensive research utilization, span-
ning from molecular biology to biochemistry and cancer
genetics, as well as clinical and public health research.
Besides the pragmatic effectiveness study, the screening trial
will be utilized for developing new methods for detecting
early clinically relevant prostate cancer. As a novel
approach, we will evaluate a sensitive artificial olfaction
system (‘eNose’) [37, 38]. The method is based on ion
mobility spectrometry, a differential mobility spectrometry
and a field-asymmetric ion mobility spectrometry (ENVI-
AMC, Environics Inc, Mikkeli, Finland; Owlstone Lonestar,
Owlstone Nanotech Ltd, Cambridge, UK; Juno, Chemring
Ltd, USA), capable of detecting a vast range of volatile
organic compounds at particle per million-trillion (ppm-ppt)
concentrations in a 5 ml sample. A semi-supervisedmachine
learning algorithm is developed to recognize a typical mul-
tidimensional pattern of volatile compounds (mainly ami-
nes) characterizing prostate cancer. The current setup has a
substantially improved sensitivity, while already the previ-
ous generation (with an order of magnitude lower detection
capacity) showed AUC of 0.77, with sensitivity 0.78 and
specificity of 0.67 in distinguishing prostate cancer patients
from cancer-free subjects [37, 38].
Kallikrein glycovariants have shown promise as novel
methods for detection of early, clinically relevant PrCa,
Lectin-assisted target cancer-associated changes in the car-
bohydrate moiety at Asn-45 of PSA. The rationale is based
on lectins (carbohydrate binding proteins having the unique
specificities for glycan structures), which are covalently
coupled to fluorescent nanoparticles and used to specifically
detect cancer associated glycans on PSA. From a library of
lectin nanoparticles established, the most promising lectins
will be identified to preferentially detect PSA from men with
PrCa, whereas urine or seminal plasma derived PSA of
healthy individuals remains non-reactive. Early results
demonstrate improved cancer specificity (improved dis-
crimination of high grade PrCa from biopsy negative and
Gleason score 6 patients) in urine using a plant lectin
nanoparticle-aided PSA assay [39]. Observational studies of
diagnostic accuracy of other tests will also be incorporated,
though referral will be based on the primary tests.
In conclusion, we propose a population-based screening
trial combining serum PSA and a multi-kallikrein panel as
biomarkers, with MRI-imaging to guide targeted biopsies.
A three-tiered risk stratification protocol is aimed at min-
imizing overdetection, while retaining most of the mor-
tality benefit. The final analysis of the main end-point,
prostate cancer mortality, will be at 15 years of follow-up.
Side studies of novel tests for identifying clinically relevant
disease will be carried out and a sample repository estab-
lished for etiologic and prognostic research.
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Appendix: MRI protocol
The patient preparation includes the evacuation of the
rectum and administration of antispasmolytic.
The mpMRI consists of T2WI, DWI with ADC maps and
DCE performed by 3T scanners, using a protocol in accor-
dance with PI-RADS v2 published by the American College
of Radiology in 2015. Slice thickness is 3 mm for T2WI and
DWI, and 4 mm for DCE. The T2WI are obtained with
turbo-spin-echo (TSE) sequences covering the whole pros-
tate gland and the seminal vesicles. The DWI utilize b-values
up to 800 for calculating ADC-maps and b-values up to 2000
for tumor detection. High b-value images are obtained by
calculating those images by extrapolation up to b1400 from
the acquired lower b-value data. Pre-contrast enhancement
T1W images with fat suppression are obtained to detect
haemorrhages. The DCE imaging, T1WI is performed with
intravenous administration of gadolinium-based contrast
agent with the temporal resolution of 7 s and total observa-
tion time 2 min 30 s to detect possible early enhancement.
The DCE data are visually assessed and further analyzed by
using DynaCad software to produce signal intensity curves of
each lesion detected.
All uroradiologists who read the prostate MRI scans
have attended the European Society of Uroradiology two-
day Prostate MRI course at least once, and most of them
have more than 5 years of experience in interpreting
prostate MRIs. Currently, each of them read at least 300
prostate MRIs annually.
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